Deciphera Pharmaceuticals Inc expected to post a loss of 58 cents a share - Earnings Preview

Deciphera Pharmaceuticals

02/02/2024 13:45

* Deciphera Pharmaceuticals Inc  DCPH.OQ   DCPH.O  is
expected
to show a rise in quarterly revenue when it reports  results on
February 6 for the period ending December 31 2023
    * The Waltham Massachusetts-based  company is expected to
report a
26.3% increase in revenue to $45.918 million from $36.35 million
a year ago, according to the mean estimate from 11 analysts,
based on LSEG data.The company's guidance on January 8 2024, for
the period ended December 31, was for revenue of $47.000
million.
    * ​LSEG's mean analyst estimate for Deciphera
Pharmaceuticals Inc
is for a loss of 58 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Deciphera
Pharmaceuticals Inc is $23.00​, above​ its last closing price
of $14.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.60       -0.61      -0.58     Beat    4.7
 Jun. 30 2023  -0.61       -0.62      -0.57     Beat    8.1
 Mar. 31 2023  -0.58       -0.59      -0.60     Missed  -1.1​
 Dec. 31 2022  -0.55       -0.56      -0.60     Missed  -7.6
 ​​Sep.        -0.57       -0.58      -0.55     Beat    4.6
 30 2022                                                
 Jun. 30 2022  -0.65       -0.66      -0.60     Beat    8.8​
 Mar. 31 2022  -0.94       -0.90      -0.80     Beat    11.2
 Dec. 31 2021  -1.49       -1.38      -1.51     Missed  -9.5
 This summary was machine generated February 2 at 13:45 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)